

PGPB, USPT; PLUR=YES; OP=ADJ

<u>L8</u> L2 and allerg\$	5 <u>L8</u>
<u>L7</u> L6.clm.	2 <u>L7</u>
<u>L6</u> (cd40)same (Antibod\$) same (allerg\$ or ige)same (treat\$ or inhibit\$ or block\$ or suppress\$ or prevent\$ or therap\$ or antagoni\$)	232 <u>L6</u>
<u>L5</u> (cd40)same (Antibod\$) and (allerg\$ or ige)same (treat\$ or inhibit\$ or block\$ or suppress\$ or prevent\$ or therap\$ or antagoni\$)	836 <u>L5</u>
<u>L4</u> (cd40) and (5d12 or 3a8 or 3c6)same (antibod\$ or hybridoma\$) and (allerg\$ or ige)	17 <u>L4</u>
<u>L3</u> (cd40) and (5d12 or 3a8 or 3c6)same (antibod\$ or hybridoma\$)	19 <u>L3</u>
<u>L2</u> L1 and (cd40) and (5d12 or 3a8 or 3c6)	6 <u>L2</u>
<u>L1</u> de boer.in.	

oa / 954764

**Search Results - Record(s) 1 through 6 of 6 returned.**

- 
1. 6315998. 15 Feb 00; 13 Nov 01. Methods of blocking B-cell activation using anti-CD40 monoclonal antibodies. de Boer; Mark, et al. 424/144.1; 424/130.1 424/133.1 424/141.1 424/143.1 424/153.1 424/173.1 530/387.1 530/387.3 530/388.1 530/388.2 530/388.22 530/388.7 530/388.73. A61K039/395 C07K016/28.
- 
2. 6056959. 05 Jun 95; 02 May 00. CD40 antigen antibody complex. de Boer; Mark, et al. 424/178.1; 424/130.1 424/133.1 424/141.1 424/143.1 424/153.1 424/173.1 424/184.1 530/350 530/387.1 530/387.3 530/388.1 530/388.2 530/388.22 530/388.73. A61K039/395 A61K035/28 C07K016/28 C07K014/435.
- 
3. 6004552. 05 Jun 95; 21 Dec 99. Methods of blocking B cell proliferation using anti-CD40 monoclonal antibodies. de Boer; Mark, et al. 424/144.1; 424/130.1 424/133.1 424/141.1 424/143.1 424/153.1 424/173.1. A61K039/395.
- 
4. 5874082. 23 Feb 96; 23 Feb 99. Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation. de Boer; Mark. 424/153.1; 424/130.1 424/133.1 424/141.1 424/143.1 424/144.1 424/173.1 530/387.3 530/388.22 530/388.7 530/388.73. A61K039/395 C07K016/28.
- 
5. 5677165. 28 May 93; 14 Oct 97. Anti-CD40 monoclonal antibodies capable of blocking B-cell activation. de Boer; Mark, et al. 435/343.1; 435/70.21 530/388.22 530/388.73. C12N005/12 C07K015/28.
- 
6. 5397703. 09 Jul 92; 14 Mar 95. Method for generation of antibodies to cell surface molecules. De Boer; Mark, et al. 424/93.21; 435/451 435/452 435/456 435/467 435/6 530/389.1. C12N015/02 C12N015/06 A61K039/00.

**Search Results - Record(s) 1 through 10 of 19 returned.**

- 
1. [20040071656](#). 23 Dec 02. 15 Apr 04. Modulation of heat-shock-protein-based immunotherapies. Wieland, Felix, et al. 424/85.1; 424/185.1 424/85.2 A61K039/00 A61K038/19 A61K038/20.
- 
2. [20030226155](#). 10 Mar 03. 04 Dec 03. Modified transferrin-antibody fusion proteins. Sadeghi, Homayoun, et al. 800/7; 424/178.1 530/391.1 A01K067/027 A61K039/395 C07K016/46.
- 
3. [20030211075](#). 27 Sep 02. 13 Nov 03. Combined compositions for tumor vasculature coagulation and treatment. Thorpe, Philip E., et al. 424/85.1; 514/12 514/323 514/54 514/733 A61K038/19 A61K031/739 A61K038/18 A61K031/454 A61K031/05.
- 
4. [20030165499](#). 23 Jan 03. 04 Sep 03. Compositions and methods for treating psoriasis. Chu, Keting, et al. 424/141.1; 424/144.1 514/1 A61K039/395 A61K031/00.
- 
5. [20030148353](#). 17 Dec 02. 07 Aug 03. Method for in vitro molecular evolution of protein function. Borrebaeck, Carl Arne Krister, et al. 435/6; 435/91.2 C12Q001/68 C12P019/34.
- 
6. [20030139374](#). 27 Sep 02. 24 Jul 03. Combined methods for tumor vasculature coagulation and treatment. Thorpe, Philip E., et al. 514/54; A61K031/739.
- 
7. [20030129193](#). 27 Sep 02. 10 Jul 03. Combined methods for tumor vasculature coaguligand treatment. Thorpe, Philip E., et al. 424/155.1; 424/85.1 514/12 514/721 514/8 A61K039/395 A61K038/16 A61K038/19 A61K038/14 A61K031/075.
- 
8. [20030124132](#). 27 Sep 02. 03 Jul 03. Combined compositions for tumor vasculature coaguligand treatment. Thorpe, Philip E., et al. 424/178.1; 514/54 A61K039/395 A61K031/739.
- 
9. [20030059427](#). 26 Oct 01. 27 Mar 03. Isolation and characterization of highly active anti-CD40 antibody. Force, Walker R., et al. 424/144.1; 435/7.92 530/388.22 A61K039/395 G01N033/53 G01N033/537 G01N033/543 C07K016/28.
- 
10. [20020155502](#). 30 Oct 01. 24 Oct 02. Affinity maturation by competitive selection. Balint, Robert F., et al. 435/7.1; 435/7.2 435/7.32 G01N033/53 G01N033/567 G01N033/554 G01N033/569.
- 

**Generate Collection****Print**

Term	Documents
CD40	3464
CD40S	0
5D12	27
5D12S	0
3A8	152
3A8S	0
3C6	109
3C6S	0

- 
11. 20020150559. 15 Oct 01. 17 Oct 02. Induction of T cell tolerance with CD40/B7 antagonists. DeBoer, Mark, et al. 424/93.6; 424/93.21 435/372 530/388.22 A61K048/00 C12N005/08 C07K016/28.
12. 20020106371. 18 Sep 01. 08 Aug 02. Method for treating an IgE-mediated disease in a patient using anti-CD40 monoclonal antibodies. Boer, Mark de, et al. 424/144.1; 424/131.1 530/387.2 A61K039/395 C07K016/42.
13. 20020031512. 19 Apr 01. 14 Mar 02. CD40 antagonists for use in treating psoriasis and other inflammatory skin conditions. Pasch, M. C., et al. 424/141.1; 424/144.1 A61K039/395.
14. 6315998. 15 Feb 00; 13 Nov 01. Methods of blocking B-cell activation using anti-CD40 monoclonal antibodies. de Boer; Mark, et al. 424/144.1; 424/130.1 424/133.1 424/141.1 424/143.1 424/153.1 424/173.1 530/387.1 530/387.3 530/388.1 530/388.2 530/388.22 530/388.7 530/388.73. A61K039/395 C07K016/28.
15. 6056959. 05 Jun 95; 02 May 00. CD40 antigen antibody complex. de Boer; Mark, et al. 424/178.1; 424/130.1 424/133.1 424/141.1 424/143.1 424/153.1 424/173.1 424/184.1 530/350 530/387.1 530/387.3 530/388.1 530/388.2 530/388.22 530/388.73. A61K039/395 A61K035/28 C07K016/28 C07K014/435.
16. 6004552. 05 Jun 95; 21 Dec 99. Methods of blocking B cell proliferation using anti-CD40 monoclonal antibodies. de Boer; Mark, et al. 424/144.1; 424/130.1 424/133.1 424/141.1 424/143.1 424/153.1 424/173.1. A61K039/395.
17. 5874082. 23 Feb 96; 23 Feb 99. Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation. de Boer; Mark. 424/153.1; 424/130.1 424/133.1 424/141.1 424/143.1 424/144.1 424/173.1 530/387.3 530/388.22 530/388.7 530/388.73. A61K039/395 C07K016/28.
18. 5677165. 28 May 93; 14 Oct 97. Anti-CD40 monoclonal antibodies capable of blocking B-cell activation. de Boer; Mark, et al. 435/343.1; 435/70.21 530/388.22 530/388.73. C12N005/12 C07K015/28.
19. 5397703. 09 Jul 92; 14 M

**Search Results - Record(s) 1 through 5 of 5 returned.**

1. Document ID: US 6315998 B1

**Using default format because multiple data bases are involved.**

L8: Entry 1 of 5

File: USPT

Nov 13, 2001

US-PAT-NO: 6315998

DOCUMENT-IDENTIFIER: US 6315998 B1

TITLE: Methods of blocking B-cell activation using anti-CD40 monoclonal antibodies

DATE-ISSUED: November 13, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
de Boer; Mark	Beuerwijk			NL
Conroy; Leah B.	Pacifica	CA		

US-CL-CURRENT: 424/144.1; 424/130.1, 424/133.1, 424/141.1, 424/143.1, 424/153.1,  
424/173.1, 530/387.1, 530/387.3, 530/388.1, 530/388.2, 530/388.22, 530/388.7,  
530/388.73

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Specifications](#) | [Attachments](#) | [Claims](#) | [KMC](#) | [Drawn D](#)

- 
2. Document ID: US 6056959 A

L8: Entry 2 of 5

File: USPT

May 2, 2000

US-PAT-NO: 6056959

DOCUMENT-IDENTIFIER: US 6056959 A

TITLE: CD40 antigen antibody complex

DATE-ISSUED: May 2, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
de Boer; Mark	Beverwyk			NL
Conroy; Leah B.	Pacifica	CA		

US-CL-CURRENT: 424/178.1; 424/130.1, 424/133.1, 424/141.1, 424/143.1, 424/153.1,  
424/173.1, 424/184.1, 530/350, 530/387.1, 530/387.3, 530/388.1, 530/388.2,  
530/388.22, 530/388.73

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Specifications](#) | [Attachments](#) | [Claims](#) | [KMC](#) | [Drawn D](#)

- 
3. Document ID: US 6004552 A

L8: Entry 3 of 5

File: USPT

Dec 21, 1999

US-PAT-NO: 6004552  
DOCUMENT-IDENTIFIER: US 6004552 A

TITLE: Methods of blocking B cell proliferation using anti-CD40 monoclonal antibodies

DATE-ISSUED: December 21, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
de Boer; Mark	Beuerwyk			NL
Conroy; Leah B	Pacifica	CA		

US-CL-CURRENT: 424/144.1; 424/130.1, 424/133.1, 424/141.1, 424/143.1, 424/153.1,  
424/173.1

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Abstracts](#) | [Inventors](#) | [Claims](#) | [KMC](#) | [Drawn D](#)

---

4. Document ID: US 5874082 A

L8: Entry 4 of 5

File: USPT

Feb 23, 1999

US-PAT-NO: 5874082

DOCUMENT-IDENTIFIER: US 5874082 A

**\*\* See image for Certificate of Correction \*\***

TITLE: Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation

DATE-ISSUED: February 23, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
de Boer; Mark	Heemskerk			NL

US-CL-CURRENT: 424/153.1; 424/130.1, 424/133.1, 424/141.1, 424/143.1, 424/144.1,  
424/173.1, 530/387.3, 530/388.22, 530/388.7, 530/388.73

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Abstracts](#) | [Inventors](#) | [Claims](#) | [KMC](#) | [Drawn D](#)